

Asthma Indicators for LHIN 7: Toronto Central

Indicator	Asthma Indicators for LHIN 7: Toronto Central																						
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017*	2018*
1. PFT used for diagnosis (% of incident asthma) [†]	49.72	50.01	48.18	47.60	43.97	44.28	44.65	42.50	41.92	44.72	43.64	45.51	48.45	47.81	48.03	47.80	47.30	52.41	51.81	52.95	52.97	53.10	57.71
2. PFT used for monitoring (% of prevalent asthma) [†]	17.35	16.21	15.28	13.64	12.56	11.83	10.68	9.73	9.10	8.92	8.66	8.38	7.92	7.88	7.82	7.57	7.22	6.95	7.08	7.27	7.14	6.99	6.94
3. ≥1 ICS prescription (% of prevalent asthma) [‡]	51.68	50.40	49.13	48.02	48.13	48.35	47.32	45.47	45.62	45.34	44.38	44.37	43.99	44.28	44.50	45.92	45.63	45.92	45.20	45.55	44.51	41.99	39.41
4. ≥1 β2-agonist prescription (% of prevalent asthma) [‡]	54.61	53.15	51.59	49.72	49.00	46.60	43.28	40.98	39.28	38.33	36.33	35.54	32.79	32.03	31.80	32.15	30.94	30.66	28.12	21.52	21.37	20.23	20.36
5. ≥1 asthma ED visit (% of prevalent asthma)	3.11	2.73	2.42	2.43	2.46	2.11	2.26	1.96	1.85	1.83	1.79	1.69	1.47	1.37	1.27	1.18	1.10	1.06	0.97	0.97	0.86	0.83	0.81
6. ≥1 asthma physician office visit (% of prevalent asthma)	39.41	35.90	33.40	31.01	29.00	28.58	25.59	23.48	22.64	21.85	21.12	20.27	18.78	18.06	17.93	16.56	15.60	15.11	14.62	14.28	13.85	13.57	13.27
7. β2-agonist use (% of prevalent asthma) [‡]																							
0	45.39	46.85	48.41	50.28	51.00	53.40	56.72	59.02	60.72	61.67	63.67	64.46	67.21	67.97	68.20	67.85	69.06	69.34	71.88	78.48	78.63	79.77	79.64
1-2	17.24	18.46	18.10	17.72	18.04	17.76	16.73	16.13	15.94	16.51	16.01	15.71	15.07	15.33	15.44	15.61	14.94	15.49	14.62	10.85	10.72	10.13	10.29
≥3	37.37	34.70	33.49	32.01	30.96	28.84	26.56	24.85	23.34	21.82	20.32	19.83	17.72	16.70	16.35	16.54	16.00	15.16	13.50	10.67	10.65	10.09	10.07

*Reporting period is from April 1996 to March 2019. Data for 2017 and 2018 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services use

[†]PFT data refers to individuals aged 7-99 years in the asthma prevalent population.

[‡]Drug use data refers to individuals aged 66-99 years with complete year ODB coverage in the asthma prevalent population.

Technical notes:

^aOHIP data was up to December 2019 when the tables were created.

^bFor asthma incidence from July 2017 to March 2019, PFT data for 2.5-year post asthma incidence are not complete as latest data were available up to December 2019 when the tables were created.

^cIndividuals with missing LHIN, rurality, or without OHIP coverage were excluded.

^dAsthma incidence of the year were excluded from this table, except for indicator 1.

^eIndex date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.

Asthma indicators - detailed description:

1. Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date^{a-c}
2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date^{a,c-e}
3. Percent of asthma prevalence 66 years and above with at least one prescription of ICS in one year prior to the index date^{c-e}
4. Percent of asthma prevalence aged 66 years and above with at least one prescription of β2-agonist in one year prior to the index date^{c-e}
5. Percent of asthma prevalence with at least one ED visit in one year prior to the index date^{c-e}
6. Percent of asthma prevalence with at least one physician office visit in one year prior to the index date^{c-e}
7. Distribution of the three categories of β2-agonist use for asthma prevalence aged 66 years and above^{c,d}

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.